Genocea Biosciences Inc
NASDAQ:GNCA
Intrinsic Value
Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of GNCA.
Genocea Biosciences Inc's market capitalization is 11.7k USD.
GNCA stock price is 0.0002 USD.
GNCA.
GNCA. Open DCF Valuation
GNCA. Open Relative Valuation
GNCA.
GNCA's short-term assets (24m USD) exceed its short-term liabilties (18m USD).
GNCA's long-term assets (39m USD) exceed its long-term liabilties (26m USD).
GNCA has negative Operating Income for the last twelve months.
GNCA has negative Net Income for the last twelve months.
GNCA's ROE (Return on Equity) for the past 12 months is negative and is equal to -526%.
GNCA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -317%.
GNCA has negative Free Cash Flow for the last twelve months.
GNCA's D/E (Debt to Equity) is very low and is equal to 0.24.
GNCA has negative three-year average ROE (Return on Equity): -184%. The company is not efficient at transforming stockholders' equity into net income.
GNCA has negative three-year average ROIC (Return on Invested Capital): -285%. The company is not efficient at using invested capital to generate operating income.
GNCA has negative Net Debt. This means that the company has more cash and short-term investments (20m USD) than debt (3m USD).
GNCA's Altman Z-Score is very low and is equal to -18.72.
GNCA doesn't generate enough operating income (-55m USD) to safely cover interest payments on its debt (547k USD).
Fundamental Analysis
Genocea Biosciences Inc
Balance Sheet Decomposition
Genocea Biosciences Inc
| Current Assets | 24.4m |
| Cash & Short-Term Investments | 20.1m |
| Other Current Assets | 4.3m |
| Non-Current Assets | 14.4m |
| PP&E | 13.5m |
| Other Non-Current Assets | 884k |
| Current Liabilities | 18m |
| Accounts Payable | 594k |
| Accrued Liabilities | 10m |
| Other Current Liabilities | 7.5m |
| Non-Current Liabilities | 8.4m |
| Long-Term Debt | 2.9m |
| Other Non-Current Liabilities | 5.4m |
Earnings Waterfall
Genocea Biosciences Inc
|
Revenue
|
1.9m
USD
|
|
Operating Expenses
|
-57.4m
USD
|
|
Operating Income
|
-55.4m
USD
|
|
Other Expenses
|
18.3m
USD
|
|
Net Income
|
-37.2m
USD
|
Free Cash Flow Analysis
Genocea Biosciences Inc
GNCA Profitability Score
Profitability Due Diligence
Genocea Biosciences Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Genocea Biosciences Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
GNCA Solvency Score
Solvency Due Diligence
Genocea Biosciences Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Score
Genocea Biosciences Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GNCA Price Targets Summary
Genocea Biosciences Inc
Ownership
GNCA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
GNCA Price
Genocea Biosciences Inc
| Average Annual Return | -34.02% |
| Standard Deviation of Annual Returns | 36.25% |
| Max Drawdown | -100% |
| Market Capitalization | 11.7k USD |
| Shares Outstanding | 58 783 500 |
| Percentage of Shares Shorted | 3.4% |
Company Profile
Genocea Biosciences Inc
Country
Industry
Market Cap
Dividend Yield
Description
Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. The company is headquartered in Cambridge, Massachusetts and currently employs 74 full-time employees. The company went IPO on 2014-02-05. The firm is focused on discovering and developing cancer immunotherapies using its Antigen Lead Acquisition System (ATLAS) platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by sequencing of that patient's tumor. Its product candidates include GEN-011 and GEN-009. GEN-011 is an investigational solid tumor cell therapy candidate, which consists of CD4+ and CD8+ neoantigen-targeted peripheral T cells (NPTs) which are specific for up to 30 antigens, designed to limit tumor escape. GEN-011 consists of T cells extracted from the patient’s peripheral blood and specific for ATLAS-prioritized neoantigens. GEN-009 is a neoantigen vaccine candidate delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The firm is evaluating its Phase I/IIa of GEN-009.
You don't have any saved screeners yet
